Abstract:
:The purpose of the present study was to perform a BPH risk factor analysis in men, relating the prostate gland volume to components of the metabolic syndrome and to identify clues to the etiology of BPH. Our material comprised a consecutive series of 158 patients with lower urinary tract symptoms with or without manifestations of the metabolic syndrome. In this group, the measured volume of the prostate was related consecutively to potential risk factors. The diagnoses atherosclerosis, non-insulin-dependent diabetes mellitus (NIDDM) and treated hypertension were obtained from the patient's medical history. Data on blood pressure, waist and hip measure, body height and weight were collected and body mass index (BMI) and waist/hip ratio (WHR) were calculated. Blood samples were drawn from fasting patients to determine insulin, cholesterol, triglycerides, HDL and LDL-cholesterol, uric acid and ALAT. The prostate gland volume was determined using ultrasound. Our results show that there was a larger prostate gland in men with NIDDM (P=0.0058), treated hypertension (P=0.0317), obesity (P<0.0001), low HDL-cholesterol levels (P=0.0132) and high insulin levels (P<0.0001) than in men without these conditions. The prostate gland volume correlated positively with the systolic blood pressure (r(s)=0.17; P=0.03), obesity (r(s)=0.34; P<0.0001) and fasting insulin (r(s)=0.38; P<0.0001) and negatively with HDL-cholesterol (r(s)=-0.22; P=0.009). On the basis of our findings, we concluded that NIDDM, treated hypertension, obesity, low HDL-cholesterol levels and high insulin levels constitute risk factors for the development of BPH. The results suggest that BPH is a facet of the metabolic syndrome and that BPH patients may share the same metabolic abnormality of a defective insulin-mediated glucose uptake and secondary hyperinsulinemia as patients with the metabolic syndrome. The findings generate a hypothesis of a causal relationship between high insulin levels and the development of BPH. In a clinical setting, the findings of the present report suggest that, in any patient presenting with BPH, the possible presence of NIDDM, hypertension, obesity, high insulin and low HDL-cholesterol levels should be considered. Conversely, in patients suffering from these conditions, the possibility of a clinically important BPH should be kept in mind.
journal_name
Prostate Cancer Prostatic Disjournal_title
Prostate cancer and prostatic diseasesauthors
Hammarsten J,Högstedt B,Holthuis N,Mellström Ddoi
10.1038/sj.pcan.4500221subject
Has Abstractpub_date
1998-03-01 00:00:00pages
157-162issue
3eissn
1365-7852issn
1476-5608pii
4500221journal_volume
1pub_type
杂志文章abstract:BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-020-0224-4
更新日期:2020-12-01 00:00:00
abstract:BACKGROUND:Berbamine (BBM) has been reported with antitumor activities. BBM inhibited the growth of prostate cancer (PCa) cells and caused vacuolization of mitochondria in preliminary study. We hypothesized BBM could enhance apoptosis of PCa cells through mitochondrial pathway. METHODS:Growth of PC-3 and LNCaP cells t...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2016.29
更新日期:2016-12-01 00:00:00
abstract::New approaches to treat prostate cancer (PCA) are utilizing gene therapy and aim to correct the disease at the genetic level. Getting a gene efficiently into the target cell is the subject of much interest. We used a holmium laser for transfecting rat PCA cells with the reporter gene pEGFP. By FACS analysis and fluore...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500653
更新日期:2003-01-01 00:00:00
abstract:BACKGROUND:Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant hormonal therapy (NHT) before radical prostatectomy (RP). The majority of them included mainly low and intermediate risk prostate cancer (PCa) without specifically assessing PCa-related death (PCRD). Thus, there i...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2017.29
更新日期:2017-12-01 00:00:00
abstract::The current management of locally advanced prostate cancer generally involves treatment with radiotherapy, hormone therapy or a combination of both. Of particular importance when choosing the type and duration of treatment is the patient's risk category, which predicts the risk of subclinical metastases based on prost...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500620
更新日期:2002-01-01 00:00:00
abstract::We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who had neither neoadjuvant therapy nor postoperative adjuvant hormon...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2008.18
更新日期:2008-01-01 00:00:00
abstract::The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, w...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4501001
更新日期:2008-01-01 00:00:00
abstract::In light of the growing interest in the concept of 'uroselectivity' and in the increased worldwide use of alpha-blockers for benign prostatic hyperplasia (BPH), this review evaluates the relative benefits of various alpha-blocking agents in the treatment of BPH. The pharmacological and physiological selectivity as wel...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500302
更新日期:1999-05-01 00:00:00
abstract:BACKGROUND:To determine the evolution of prostatic multi-parametric magnetic resonance imaging (mp-MRI) signal following transrectal ultrasound (TRUS)-guided biopsy. METHODS:Local ethical permission and informed written consent was obtained from all the participants (n=14, aged 43-69, mean 64 years). Patients with a c...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2015.33
更新日期:2015-12-01 00:00:00
abstract::Skeletal morbidity secondary to metastases and osteoporosis is common in patients with advanced prostate cancer. Despite the typically sclerotic nature of prostate cancer metastases, osteoclast mediated osteolysis may play a significant role. This review addresses the newly recognised antitumour effects of bisphosphon...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/sj.pcan.4500607
更新日期:2002-01-01 00:00:00
abstract:BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,多中心研究
doi:10.1038/pcan.2014.13
更新日期:2014-09-01 00:00:00
abstract::We have identified a novel function for a member of the transient receptor potential (TRP) protein super-family, TRPM2, in prostate cancer cell proliferation. TRPM2 encodes a non-selective cation-permeable ion channel. We found that selectively knocking down TRPM2 with the small interfering RNA technique inhibited the...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2009.55
更新日期:2010-06-01 00:00:00
abstract::Worldwide disparities exist between geographic regions with regard to prostate cancer incidence and mortality. Countries in East Asia have lower rates of prostate cancer compared with Western countries such as Canada and the US. Some suggest that dietary differences between the two geographic regions, particularly the...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/sj.pcan.4500953
更新日期:2007-01-01 00:00:00
abstract:BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2013.33
更新日期:2013-12-01 00:00:00
abstract:BACKGROUND:Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,随机对照试验
doi:10.1038/s41391-017-0030-9
更新日期:2018-06-01 00:00:00
abstract::The Gyrus system uses bipolar electrocautery with saline irrigation to vaporize prostatic tissue and is compared to transurethral resection of the prostate (TURP) in a randomized prospective study with 1 y follow-up. Outcomes measured were fluid absorption, blood loss, period of catheterization, hospital stay, symptom...
journal_title:Prostate cancer and prostatic diseases
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1038/sj.pcan.4500631
更新日期:2003-01-01 00:00:00
abstract:BACKGROUND:Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we exami...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2016.38
更新日期:2016-12-01 00:00:00
abstract::The TGFBR1*6A (*6A) variant in exon 1 of the TGFBR1 gene has been postulated as a putative tumor susceptibility allele in several studies. We have performed a case-control study in 537 men with histologically verified prostate cancer and in 488 unrelated controls to investigate the association of *6A with prostate can...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500765
更新日期:2005-01-01 00:00:00
abstract:BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-019-0197-3
更新日期:2020-09-01 00:00:00
abstract::The aim of the present study was to evaluate how serum testosterone level (T) can affect urinary continence and erectile function in patients undergoing radical prostatectomy (RP). We included 257 patients with clinically localized prostate cancer, those who had filled out preoperative quality of life questionnaires (...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2010.4
更新日期:2010-06-01 00:00:00
abstract:PURPOSES:To address prostate cancer (PCa) detection with respect to the number of biopsy sessions performed, to identify risk factors for detection after a negative biopsy, and to analyze the clinical characteristics of the detected tumors. SCOPE:Only biopsied men (sextant) were included. A total of 1011 biopsy sessio...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500730
更新日期:2004-01-01 00:00:00
abstract:BACKGROUND:Unlike in other mouse models of atherogenesis, it has recently been suggested that orchiectomy plays a role in accelerating atherosclerosis and inhibiting the progression of cardiovascular disease in the ApoE-/-:Ins2+/Akita mouse model of hyperglycemia. Androgen-deprivation therapy (ADT) is a common treatmen...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-020-00288-y
更新日期:2020-09-28 00:00:00
abstract:BACKGROUND:Tumor contact length (TCL) is defined as the extent of contact between prostate cancer and the prostatic capsule, and its predictive value for microscopic extraprostatic extension (EPE) has been reported. However, the impact of the zonal origin (anterior or posterior tumor) of the tumor on the diagnosis of E...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-019-0136-3
更新日期:2019-12-01 00:00:00
abstract:INTRODUCTION:Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500889
更新日期:2006-01-01 00:00:00
abstract:PURPOSE:To determine whether quantitative flow cytometric androgen receptor density expression (MFC ratio) in prostate cancer was associated with S-phase fraction. METHODS:Flow cytometry was performed to determine DNA aneuploidy, S-phase fraction, percentage of androgen receptor (AR)-positive cells, and MFC ratio in p...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500672
更新日期:2003-01-01 00:00:00
abstract::To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/sj.pcan.4500552
更新日期:2002-01-01 00:00:00
abstract::'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/sj.pcan.4500963
更新日期:2007-01-01 00:00:00
abstract::We measured the histologic stromal and epithelial tissue components of the benign (normal) and malignant tissue compartments of Japanese-Americans (J-A) and native Japanese (NJ) men living in Japan. The patient cohort included 25 NJ men undergoing radical prostatectomy (RP) in Nagoya, Japan and 25 J-A (second or third...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500738
更新日期:2004-01-01 00:00:00
abstract::Radiofrequency interstitial tumor ablation (RITA) is a thermal ablation method that uses needles and low radiofrequency (RF) energy. The aim of our study was to evaluate the histopathology of thermal lesions induced by RF energy delivered interstitially in prostate cancer patients who subsequently underwent prostatect...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500877
更新日期:2006-01-01 00:00:00
abstract:BACKGROUND:Intermittent androgen deprivation (IAD) for prostate cancer was studied with the objective of reducing the side effects of treatment and potentially delaying the development of hormone resistance. There also appears to be a quality of life benefit during off-treatment intervals owing to the recovery of serum...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1038/pcan.2012.12
更新日期:2012-09-01 00:00:00